Table 2.

Analysis of mucosal thickness (μm) in different treatment groups determined by OCT imaging at different time points

Table 2A. Statistical analysis of effects of mutant K-RAS and Sulindac on mucosal thickness

GroupWeek 13Week 18Week 22Week 26Week 30Week 34
Vil-Cre negative K-rasG12D
 Control no sulindac102 ± 18a103 ± 14109 ± 14106 ± 18109 ± 13120 ± 26
 Control sulindac107 ± 17111 ± 32110 ± 17118 ± 18120 ± 27108 ± 17
K-ras wt
 Control no sulindac125 ± 20127 ± 24131 ± 35128 ± 31124 ± 27124 ± 24
 Control sulindac108 ± 2119 ± 33107 ± 24111 ± 25105 ± 23126 ± 11
K-rasG12D
 Control no sulindac186 ± 37191 ± 32182 ± 40178 ± 47178 ± 29169 ± 35
 Control sulindac137 ± 37148 ± 50150 ± 37151 ± 49151 ± 37145 ± 34
  • aMean ± SD.